Citius Pharmaceuticals, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2022 Annual Meeting of Stockholders held on February 8, 2022. The company is incorporated in Nevada and its common stock (CTXR) and warrants (CTXRW) trade on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
Stockholders voted on four key matters at the annual meeting:
- Board of Directors Election: Seven nominees were elected for one-year terms. All nominees received majority support, though significant broker non-votes (43,816,154 shares) were recorded for each candidate.
- Executive Compensation (Say-on-Pay): Stockholders approved the advisory vote on executive compensation with 25,231,305 shares for and 9,959,507 shares against.
- Frequency of Say-on-Pay Votes: Stockholders approved a three-year frequency for future advisory votes on executive compensation. The vote was 22,674,884 shares for 3 years, compared to 12,116,746 shares for 1 year and 784,352 shares for 2 years.
- Ratification of Auditors: Stockholders ratified the selection of Wolf & Company, P.C. as the independent registered public accounting firm for the fiscal year ending September 30, 2022, with 78,435,346 shares for and 388,270 shares against.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Key Facts for Investor Verification
- Verify the total number of shares outstanding and the percentage of shares represented by the 43,816,154 broker non-votes to assess the level of active shareholder engagement.
- Review the specific compensation details for the executive team to understand the context of the "Say-on-Pay" approval.
- Confirm the fiscal year-end date (September 30) for future financial reporting expectations.
- Check subsequent filings for the company's financial performance, as this 8-K contains no financial data.